Dr. Robert (Bob) Meyer brings more than 30 years of experience in regulatory, industry, and academic leadership, with deep expertise in drug development, regulatory strategy, and product evaluation. His career includes senior leadership roles at the U.S. Food and Drug Administration (FDA), Merck & Co., Inc., the University of Virginia, and Greenleaf Health.
During his FDA career, Bob served as Director of the Office of Drug Evaluation II within the Center for Drug Evaluation and Research (CDER), where he oversaw the review of pulmonary and allergy, metabolic and endocrine, analgesic and anesthetic, and rheumatologic drug products. Earlier, he held several roles within CDER’s Division of Pulmonary and Allergy Drug Products, including medical reviewer, team leader, and, from 1999 to 2002, Division Director.
While at FDA, Bob chaired the development of CDER’s Pre-Market Risk Assessment guidance and participated in several Prescription Drug User Fee Act (PDUFA) negotiations on behalf of the Agency. After leaving FDA, he led global regulatory and safety at Merck & Co., Inc. and later participated in PDUFA negotiations with the Pharmaceutical Research and Manufacturers of America (PhRMA), where he also chaired the Regulatory Affairs Coordinating Committee.
Dr. Meyer subsequently served as Director of the Virginia Center for Translational and Regulatory Sciences at the University of Virginia School of Medicine and, most recently, as Principal, Drug and Biological Products, at Greenleaf Health, now ELIQUENT Life Sciences. He also serves as an independent director for Avalyn Pharma, and previously for Translate Bio (acquired by Sanofi), and Chimerix (acquired by Jazz Pharmaceuticals), as well as a former member of the Board of Trustees for the United States Pharmacopeia.